Impact of Atopic Dermatitis and Chronic Hand Eczema on Quality of Life Compared With Other Chronic Diseases

Capucci, Silvia; Hahn-Pedersen, Julie; Vilsbøll, Andreas Westh; Kragh, Nana

doi:10.1097/der.0000000000000598

Cited by 31 publications

(30 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some participants even indicated having had a suicidal thoughts because of their eczema. Even though CHE has been known to affect a person's quality of life, our findings again underline the importance of psychosocial support 2,21‐23 . Other studies also point to the need for more attention to the psychosocial impact 21,22 .…”

Section: Discussionsupporting

confidence: 57%

Patients' perspectives on quality of care for chronic hand eczema: A qualitative study

et al. 2022

View full text Add to dashboard Cite

Background Hand eczema (HE) has a significant impact on patients’ quality of life and work‐related activities. However, little is known about the patients' perspectives on quality of care for HE. Objectives To evaluate the patient perspective of the HE care process in a tertiary referral center. Methods Qualitative, semi‐structured focus groups were carried out, recorded, transcribed, and analysed using an inductive‐deductive thematic approach. Results Fifteen patients participated in four focus groups. Time and attention, together with being listened to and understood by the health care professional, were the most important aspects of care for HE mentioned by participants. Other aspects of care that were regarded as important were that diagnoses, causes and follow‐up of HE were not always clear to the participant; more psychosocial support was needed, and that participants experienced frequent changes in doctors. Information provided by nurses was valuable, but more individualized advice was needed. Conclusions To better meet the needs of patients, more explanation should be given about the causes of HE and the final diagnosis. Besides focusing on the treatment, it is also important to focus on its impact on the patient and options for psychosocial and peer support should be discussed. Furthermore, the beneficial role of the specialized nurse as part of integrated care was emphasized.

show abstract

Section: Discussionsupporting

confidence: 57%

Patients' perspectives on quality of care for chronic hand eczema: A qualitative study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Atopic dermatitis is associated with significant comorbidities, for example, asthma and food allergies [12][13][14]. Moreover, atopic dermatitis ranks second among skin and subcutaneous diseases in direct disabling consequences such as itch and social stigmatization [6], and is associated with a substantial burden on quality of life, including sleep, mental health, physical functioning, social functioning, and work productivity [15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

et al. 2021

View full text Add to dashboard Cite

Background Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery. Method Pharmacokinetic data were obtained from three double-blind, vehicle-controlled studies in patients with AD: a phase II study with ruxolitinib cream 0.15%, 0.5%, or 1.5% once daily or 1.5% twice daily (BID), and two phase III studies with 0.75% or 1.5% BID. Effects of baseline characteristics on pharmacokinetics were examined. Correlations were attempted between plasma concentrations and change in hematological parameters over time. Results Ruxolitinib plasma concentrations at steady-state (C ss ) increased with cream strength in a less-than-dose-proportional manner. In the phase III studies, overall mean (standard deviation [SD]) C ss after ruxolitinib cream 0.75% and 1.5% BID (23.8 [35.0] and 35.7 [55.0] nM) were a fraction of the half-maximal inhibitory concentration for thrombopoietin-stimulated phosphorylated STAT3 inhibition (281 nM), a JAK/STAT signaling marker. Three covariates were identified for C ss : dose, percent body surface area (%BSA) treated, and baseline Investigator's Global Assessment score. Mean (SD) bioavailability of ruxolitinib cream 1.5% BID was 6.22% (7.66%). There were no correlations between C ss and any hematological changes except for a transient increase in platelets at week 2. Conclusions Plasma ruxolitinib concentrations after treatment with topical ruxolitinib cream in patients with up to 20% BSA affected by AD are not expected to lead to systemic plasma concentrations that may be associated with adverse effects commonly associated with oral JAK inhibitors. ClinicalTrials.gov NCT03011892; NCT03745638; NCT03745651.

show abstract

“…Atopic dermatitis (AD) is an inflammatory skin disease that is characterized by xerosis and intense pruritus [1], and represents a growing burden to healthcare systems worldwide [2,3], and may considerably impair patients' quality of life [4]. Over the past 30 years, its lifetime prevalence has increased rapidly, namely in the industrialized world, where it has now plateaued at 10-20% [5].…”

Section: Introductionmentioning

confidence: 99%

Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral

Egeberg

Thyssen

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: A number of treatments for atopic dermatitis (AD) are available; however, longterm treatment patterns and healthcare consumption in patients with AD are poorly described. Methods: We conducted a registry-based longitudinal drug utilization study among Danish patients with AD that were referred to their firstever visit at hospital-based dermatology clinics. Their first visit was in the period between 1 January 2005 and 31 December 2012, and patients were followed up to 5 years after their first visit. Results: In total, 8213 people with a first-time hospital dermatologist contact for AD were included in the study (3514 aged 0-9 years, 1501 aged 10-19 years, 3198 aged 20 years or older). At first visit, a baseline history of moderately potent topical corticosteroid (TCS) use was seen among 46.6% of children (0-9 years), whereas potent or very potent TCS use was more frequently among older individuals (e.g., 51.1% and 25.6% of people aged 50 years or older had used potent and very potent TCS, respectively). The median (interquartile range) annual number of visits to general practitioners was 4 (2-7) for children and 5 (2-8) for adults, in the 12 months prior to referral. Three years after referral, these numbers had decreased to 2 (1-4) and 3 (1-6), respectively. In the first year after referral, 6% of patients were prescribed systemic corticosteroids, whereas other systemic therapies were used in 5% or less. Conclusions: After referral, low proportions of patients received systemic treatment, or potent TCS. These findings highlight considerable differences in treatment patterns between general practitioners and private practice dermatologists, compared with hospital-based dermatologists, and emphasize the need for better adherence to evidence-based treatment guidelines.

show abstract

Impact of Atopic Dermatitis and Chronic Hand Eczema on Quality of Life Compared With Other Chronic Diseases

Cited by 31 publications

References 49 publications

Patients' perspectives on quality of care for chronic hand eczema: A qualitative study

Patients' perspectives on quality of care for chronic hand eczema: A qualitative study

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral

Contact Info

Product

Resources

About